Parkinsonian Disorders clinical trials
The registry lists 218 studies for Parkinsonian Disorders across more than 10 countries. 63 are recruiting or about to start. 32 of them are mainly about Parkinsonian Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 2 narrower conditions too, such as Parkinson Disease: 4,798 studies, 1,156 open.
Get an email when these change. Save the Parkinsonian Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Status
Who runs them
Institute for Neurodegenerative Disorders (10) · Adamas Pharmaceuticals, Inc. (6) · National Institute of Neurological Disorders and Stroke (NINDS) (6) · Ruijin Hospital (6) · Radboud University Medical Center (5) · AbbVie (4) · University College, London (4) · Fondazione Don Carlo Gnocchi Onlus (3)
What is being tested here
Drugs under test in Parkinsonian Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Botulinum toxin type A | 1 | 0 | 2 |
| 3-Iodobenzylguanidine | 1 | 0 | 1 |
| Fluorodopa F 18 | 1 | 0 | 1 |
| Ioflupane I-123 | 1 | 0 | 1 |
| ONO-2808 | 1 | 1 | 1 |
| Ambroxol | 1 | 1 | 1 |
| Varenicline | 1 | 0 | 1 |
| Tavapadon | 0 | 4 | 5 |
| Iodine-123 | 0 | 1 | 5 |
| Mavoglurant | 0 | 0 | 3 |
Drug classes tested here Dopamine agonists 8
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest
- Dec 2026Non-motor Symptoms and Brain Dopamine Transporter Binding · Turku University Hospital
- Dec 2026DaTSCAN Imaging in Aging and Neurodegenerative Disease · Mayo Clinic
- Dec 2026Blood Flow Restriction for Optimizing Balance in Parkinson's Disease · The University of Texas Health Science Center at San Antonio
- Dec 2026Spinal Cord Stimulation for Parkinsonism · Ruijin Hospital
- Jan 2027Parkinson's Families Project · University College, London
- Jan 2027Strength and Dual-Task on Sarcopenia in People With Parkinson's Disease · University of Valencia
- Mar 2027Saliva and Extracellular Vesicles for Neurodegenerative Diseases · Fondazione Don Carlo Gnocchi ETS
- Mar 2027Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's Disease · Second Affiliated Hospital of Soochow University
- May 2027Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01 · BlueRock Therapeutics
- Jun 2027A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic Therapy · Vima Therapeutics
Who these studies take
Of the 45 Parkinsonian Disorders studies recruiting now, 18 (40%) set no upper age limit and 9 (20%) stop at 75 or younger. 4 (9%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 12 (27%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (7%) | 3 (7%) |
| 18 | 18 (40%) | 18 (40%) |
| 30 | 24 (53%) | 24 (53%) |
| 40 | 34 (76%) | 34 (76%) |
| 50 | 43 (96%) | 43 (96%) |
| 65 | 44 (98%) | 44 (98%) |
| 75 | 40 (89%) | 40 (89%) |
| 85 | 28 (62%) | 28 (62%) |
Across all 218 studies, recruiting or not: 12% stop at 75 or younger and 5% at 65; 12% take children; <1% are for women only and 0% for men only; 26% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Parkinsonian Disorders studies take
Of 54 interventional studies with no phase under Parkinsonian Disorders, half reached primary completion within 31 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 31 mo22–45 · 54 studies | — | 33 mo19–45 · 53 studies |
| Observational | 74 mo34–… · 37 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Stopped1
- rTMS Treatment in Vascular ParkinsonismWithdrawnNov 10, 2026NCT03720691
Newly registered1
- Strength and Dual-Task on Sarcopenia in People With Parkinson's DiseaseOct 30, 2026NCT07907302
Studies
Recruiting first, then most recently updated. Showing 50 of 218. Browse all 218 → or search them.
- A Study to Evaluate the Efficacy, PK, Safety, and Tolerability of VIM0423 in Adults With Parkinson's Disease Tremor Insufficiently Responsive to Dopaminergic TherapyRecruitingNCT07804615Phase 22 countries
- AAV2-hAADC for Parkinson's Disease (PDCS-01)Not yet recruitingNCT07267065Phase 11 country
- Strength and Dual-Task on Sarcopenia in People With Parkinson's DiseaseRecruitingNCT07907302Not applicable1 country
- Slow-SPEED: Slowing Parkinson's Early Through Exercise DosageRecruitingNCT06993142Not applicable2 countries
- DaxibotulinumtoxinA for BlepharospasmRecruitingNCT07489430Phase 21 country
- VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and ParkinsonismNot yet recruitingNCT078279631 country
- A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P)Not yet recruitingNCT07825402Phase 3
- Digitally-enhanced, Decentralized, Multi-omics Observational CohortEnrolling by invitationNCT047011772 countries
- Monoamine Oxidase B PET/CT in Various MAO-B-Related DiseaseRecruitingNCT076858731 country
- Slow-SPEED-NL: Slowing Parkinson's Early Through Exercise Dosage-NetherlandsRecruitingNCT06193252Not applicable1 country
- Cross-System Effects of Acute Intermittent Hypercapnia-Based Interventions in PDRecruitingNCT07674264Not applicable1 country
- Young Onset Parkinson's Disease Subtypes and Pathogenic MechanismsRecruitingNCT077523551 country
- MIBG in Aging and Neurologic DisordersEnrolling by invitationNCT05514106Phase 41 country
- ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's DiseaseNot yet recruitingNCT07718659Phase 11 country
- Temporal Interference Noninvasive Deep Brain Stimulation for Idiopathic Parkinson's Disease and Parkinsonian Syndromes: Effects and Target ExplorationEnrolling by invitationNCT07698236Not applicable1 country
- Use of Accelerometer for Quantification of Neurogenic Orthostatic Hypotension SymptomsRecruitingNCT04782830Not applicable1 country
- Individualized Transcranial Magnetic Stimulation in Parkinsonian DisordersRecruitingNCT07570212Not applicable1 country
- Sensing in Sleep Deep Brain StimulationRecruitingNCT07636720Not applicable1 country
- Behavioral Intervention for Lifestyle Physical Activity in Parkinson's DiseaseNot yet recruitingNCT06603012Not applicable1 country
- Aim 3 Particle Swarm Optimization PIGDRecruitingNCT05934747Not applicable1 country
- Personalized rTMS Protocol Based on Functional Reserve to Enhance Ambulatory Function in PD PatientsRecruitingNCT06350617Not applicable1 country
- A Multimodal Prospective Cohort Study of ParkinsonismRecruitingNCT075538451 country
- Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PDRecruitingNCT071878431 country
- Ultralow Dose PET Imaging of 18F-FDOPAEnrolling by invitationNCT07542158Phase 21 country
- Blood Flow Restriction for Optimizing Balance in Parkinson's DiseaseRecruitingNCT06508801Not applicable1 country
- Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With ParkinsonismNot yet recruitingNCT07471230Phase 21 country
- DaTSCAN Imaging in Aging and Neurodegenerative DiseaseEnrolling by invitationNCT01453127Phase 41 country
- Etiology-Phenotype-Outcome Pathway Study on Freezing of Gait (FOG)RecruitingNCT073860151 country
- Sleep-specific DBS Therapy in Parkinson's DiseaseRecruitingNCT05962489Not applicable1 country
- Clinical Efficacy of Intermittent Theta Burst Transcranial Magnetic Stimulation With Different Modes on Parkinson's DiseaseEnrolling by invitationNCT07176091Not applicable1 country
- Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's DiagnosisRecruitingNCT072046521 country
- Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical ActivityRecruitingNCT07324330Not applicable1 country
- The Effect of Spinal Cord Stimulation on Orthostatic Hypotension in Parkinsonism and Its Related MechanismsNot yet recruitingNCT07322458Not applicable1 country
- Observational Case Series of Patients With Parkinson's Disease (PD) Attending a Complementary Medicine Neuro-degenerative Disease (NDD) Clinic.RecruitingNCT072070961 country
- The National Registry Study For the Real-world Patients With Parkinsonian Disorders in ChinaRecruitingNCT036495031 country
- Clinical Efficacy and Mechanism of tDCS for Dysphagia in PDRecruitingNCT07153692Not applicable1 country
- Saliva and Extracellular Vesicles for Neurodegenerative DiseasesRecruitingNCT068691351 country
- Mechanism and Application of DBS in the Treatment of PDRecruitingNCT06400017Not applicable1 country
- Spinal Cord Stimulation for ParkinsonismRecruitingNCT05171205Not applicable1 country
- Ambroxol to Slow Progression in Parkinson DiseaseRecruitingNCT05778617Phase 31 country
- Effect of Adding Computerized Cognitive Training on Balance, Locomotion and Cognition in Parkinson's DiseaseRecruitingNCT06104072Not applicable1 country
- Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PDRecruitingNCT069144661 country
- An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman SpectroscopyEnrolling by invitationNCT068757391 country
- NYSCF Scientific Discovery BiobankRecruitingNCT062031061 country
- Clinical Study of Rhythmic Auditory Stimulation for Gait DisordersEnrolling by invitationNCT06837038Not applicable1 country
- Contribution of the Kinematic Theory in the Early Differential Diagnosis of the Parkinson's DiseaseRecruitingNCT061616361 country
- [18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD Vs. MSA and DLB Vs. ADRecruitingNCT06120049Phase 2/31 country
- The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related DisordersRecruitingNCT06174948Not applicable1 country
- The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's DiseaseRecruitingNCT06608355Phase 11 country
- Pesticides and Parkinson´s DiseaseRecruitingNCT064203101 country